Epidemiology, Pharmacology and Clinical Characterization of Bisphosphonate-related Osteonecrosis of the Jaw. A Retrospective Study of 70 Cases

Pelaz, Alejandro; Junquera, Luís; Gallego, Lorena; Garcı́a-Consuegra, Luis; García-Martínez, Lucía; Cutilli, T; Olay, Sonsoles

doi:10.1016/j.otoeng.2014.06.001

Cited by 10 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no significant difference in age between the groups analyzed, which suggests that age is not associated with BRONJ. 27 Although higher than most reports in the literature, [28][29][30][31] our data for BRONJ prevalence are similar to that found by Pelaz et al 32 Demographic specificities of the samples, the methods and the level of specialization of the centres where the different studies have been conducted as well as lack of consensus on the BRONJ case definition have been associated with such discrepancies of prevalence.…”

Section: Discussionsupporting

confidence: 86%

Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy

Koth

Figueiredo

Salum

et al. 2017

Dentomaxillofacial Radiology

View full text Add to dashboard Cite

Objectives: To analyze the clinical, radiographic and haematological aspects of patients under bisphosphonate therapy. Methods: A retrospective study was conducted where the records of patients taking bisphosphonates were analyzed considering the occurrence of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Evaluation included panoramic and periapical radiographies, haematological examinations and clinical features. Radiographies were analyzed determining the presence or absence of bone sclerosis, osteolysis, persisting alveolar socket, narrowing of the mandibular canal, widening of the periodontal ligament space, periradicular radiolucency, sequestrum and thickening of the lamina dura. Laboratory tests consisted of complete blood count, fasting serum glucose, erythrocyte sedimentation rate (ESR) and serum levels of calcium, phosphorus, alkaline phosphatase, parathormone (PTH) and C-terminal telopeptide of collagen I (CTX). Results: Alkaline phosphatase and ESR were significantly higher in the BRONJ group, whereas fasting serum glucose, CTX, PTH, calcium and phosphorus did not significantly differ. BRONJ showed association with smoking, tooth extraction, anaemia and leukocytosis. On radiographic analysis, persisting alveolar socket, osteolysis, bone sclerosis and narrowing of the mandibular canal were significantly more prevalent in the BRONJ group. Thickening of the lamina dura, periapical radiolucencies, widening of the periodontal ligament space and sequestrum did not significantly differ between the groups. Conclusions: BRONJ is a multifactorial disease with high morbidity, which requires experimental studies to clarify the role of the reported risk factors and clinical radiographic signs to improve its diagnosis.

show abstract

Section: Discussionsupporting

confidence: 86%

Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy

Koth

Figueiredo

Salum

et al. 2017

Dentomaxillofacial Radiology

View full text Add to dashboard Cite

show abstract

“…8−13 The treatment of BRONJ is still difficult to reach an agreement, and there is currently no effective treatment. It seems that there is no benefit in discontinuing bisphosphonate treatment because the accumulation of drugs in the bone matrix is at a high level, and the time it takes to function is much longer than the actual time: alendronate still has obvious pharmacological effects after 5 years of withdrawal, and ZA continues to reduce bone renewal after 12 istration. Furthermore, the discontinuation of bisphosphonate therapy may have serious consequences, such as bone metastases, multiple myeloma worsening, or the development of tumor-related hypercalcemia.…”

Section: ■ Introductionmentioning

confidence: 99%

“…Intravenous BPs increase the bioavailability by 140 times, and the possibility of causing BRONJ will be significantly higher than oral medication. Among BPs, zoledronic acid (ZA) is the most pathogenic, and its incidence is five times that of pamidronate. − …”

Section: Introductionmentioning

confidence: 99%

Tetrahedral Framework Nucleic Acid Promotes the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws by Promoting Angiogenesis and M2 Polarization

Zhao

Cui

Liu

et al. 2020

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Bisphosphonates are often used to treat osteoporosis, malignant bone metastases, and hypercalcemia. However, it can cause serious adverse reactions, bisphosphonate-related osteonecrosis of the jaw (BRONJ), which seriously affects the quality of life of patients. At present, the treatment of BRONJ is still difficult to reach an agreement, and there is no effective treatment. Therefore, it is very important to find effective treatments. Many studies have shown that the occurrence of BRONJ may be due to unbalanced bone turnover, anti-angiogenesis, bacterial infection, direct tissue toxicity, and abnormal immune function. The previous research results show that tetrahedral framework nucleic acids (tFNAs), a new type of nanomaterial, can promote various biological activities of cells, such as cell proliferation, migration, anti-inflammation and anti-oxidation, and angiogenesis. Therefore, we intend to explore the potential of tFNAs in the treatment of BRONJ through this study. The results show that tFNAs can promote the treatment of BRONJ by promoting angiogenesis and promoting M2 polarization in macrophages and inhibiting M1 polarization both in vitro and in vivo. These results provide a theoretical basis for the application of tFNAs in the treatment of BRONJ and also provide new ideas and methods for the treatment of other diseases based on ischemia and immune disorders.

show abstract

“…Among this class of drug, zoledronic acid is the one of choice for metastatic breast and prostate cancer (Turner et al, 2016). An important related effect of its long-term use is the development of osteonecrosis of the jaw (ONJ), mainly triggered by invasive oral procedures or even with unfavorable oral conditions, such as periodontal diseases odontogenic infections, and improperly adapted prostheses (Marx, 2003;Ruggiero et al, 2009;Pelaz et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Aged rats under zoledronic acid therapy and oral surgery

Matsumoto

Furquim

Goncalves

et al. 2017

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

show abstract

Epidemiology, Pharmacology and Clinical Characterization of Bisphosphonate-related Osteonecrosis of the Jaw. A Retrospective Study of 70 Cases

Cited by 10 publications

References 23 publications

Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy

Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy

Tetrahedral Framework Nucleic Acid Promotes the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws by Promoting Angiogenesis and M2 Polarization

Aged rats under zoledronic acid therapy and oral surgery

Contact Info

Product

Resources

About